Optimizing lipid-lowering therapy in the prevention of coronary heart disease

References

• D’Agostino B Sr, Vasan RS, Pencina MJ et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation117, 743–753 (2008).
   PubMed Web of Science ®Google Scholar
• Assmann G, Schulte H, Cullen P, Seedorf U. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study. Eur. J. Clin. Invest.37, 925–932 (2007).
   PubMed Web of Science ®Google Scholar
• Lewington S, Whitlock G, Clarke R et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet370, 1829–1839 (2007).
   PubMed Web of Science ®Google Scholar
• McQueen MJ, Hawken S, Wang X et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case–control study. Lancet372, 224–233 (2008).
   PubMed Web of Science ®Google Scholar
• Di Angelantonio E, Sarwar N, Perry P et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA302, 1993–2000 (2009).
   PubMed Web of Science ®Google Scholar
• Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation118, 993–1001 (2008).
   PubMed Web of Science ®Google Scholar
• Sarwar N, Sandhu MS, Ricketts SL et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet375, 1634–1639 (2010).
   PubMed Web of Science ®Google Scholar
• Sniderman AD, Kiss RS. The strengths and limitations of the apoB/apoA-I ratio to predict the risk of vascular disease: a Hegelian analysis. Curr. Atheroscler. Rep.9, 261–265 (2007).
   Google Scholar
• Ingelsson E, Schaefer EJ, Contois JH et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA298, 776–785 (2007).
   PubMed Web of Science ®Google Scholar
• Warnick GR, Nauck M, Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin. Chem.47, 1579–1596 (2001).
   PubMed Web of Science ®Google Scholar
• Hobbs HH, White AL. Lipoprotein(a): intrigues and insights. Curr. Opin. Lipidol.10, 225–236 (1999).
   PubMed Web of Science ®Google Scholar
• Erqou S, Kaptoge S, Perry PL et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA302, 412–423 (2009).
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med.361, 2518–2528 (2009).
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol.54, 2129–2138 (2009).
   PubMed Web of Science ®Google Scholar
• Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation109, II2–II10 (2004).
   PubMedGoogle Scholar
• Kaptoge S, Di Angelantonio E, Lowe G et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet375, 132–140 (2010).
   PubMed Web of Science ®Google Scholar
• Stewart RA, White HD, Kirby AC et al. White blood cell count predicts reduction in coronary heart disease mortality with pravastatin. Circulation111, 1756–1762 (2005).
   Google Scholar
• Caslake MJ, Packard CJ, Robertson M et al. Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Atherosclerosis210, 28–34 (2009).
   Google Scholar
• Sattar N, Murray HM, Welsh P et al. Are markers of inflammation more strongly associated with risk for fatal than for nonfatal vascular events? PLoS Med.6, e1000099 (2009).
   PubMed Web of Science ®Google Scholar
• Zacho J, Tybjaerg-Hansen A, Jensen JS et al. Genetically elevated C-reactive protein and ischemic vascular disease. N. Engl. J. Med.359, 1897–1908 (2008).
   PubMed Web of Science ®Google Scholar
• Elliott P, Chambers JC, Zhang W et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA302, 37–48 (2009).
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Kastelein JJ. C-reactive protein and cardiovascular risk: more fuel to the fire. Lancet375, 95–96 (2010).
   Google Scholar
• Ridker PM, Danielson E, Fonseca FA et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet373, 1175–1182 (2009).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med.359, 2195–2207 (2008).
   PubMed Web of Science ®Google Scholar
• Zethelius B, Berglund L, Sundstrom J et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N. Engl. J. Med.358, 2107–2116 (2008).
   PubMed Web of Science ®Google Scholar
• Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation115, 949–952 (2007).
   PubMed Web of Science ®Google Scholar
• Melander O, Newton-Cheh C, Almgren P et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA302, 49–57 (2009).
   PubMed Web of Science ®Google Scholar
• Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am. J. Cardiol.97, 3A–11A (2006).
   Web of Science ®Google Scholar
• Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation115, 114–126 (2007).
   PubMed Web of Science ®Google Scholar
• Di Angelantonio E, Danesh J, Eiriksdottir G, Gudnason V. Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med.4, e270 (2007).
   Google Scholar
• Ford I, Bezlyak V, Stott DJ et al. Reduced glomerular filtration rate and its association with clinical outcome in older patients at risk of vascular events: secondary analysis. PLoS Med.6, e16 (2009).
   PubMedGoogle Scholar
• Sattar N, McInnes IB. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr. Opin. Rheumatol.17, 286–292 (2005).
   PubMed Web of Science ®Google Scholar
• Diez Roux AV. Persistent social patterning of cardiovascular risk: rethinking the familiar. Circulation111, 3020–3021 (2005).
   Google Scholar
• Forouhi NG, Sattar N. CVD risk factors and ethnicity – a homogeneous relationship? Atheroscler. Suppl.7, 11–19 (2006).
   PubMed Web of Science ®Google Scholar
• Deans KA, Bezlyak V, Ford I et al. Differences in atherosclerosis according to area level socioeconomic deprivation: cross sectional, population based study. Br. Med. J.339, b4170 (2009).
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366, 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Hu FB, Willett WC. Optimal diets for prevention of coronary heart disease. JAMA288, 2569–2578 (2002).
   PubMed Web of Science ®Google Scholar
• Willett WC. The Mediterranean diet: science and practice. Public Health Nutr.9, 105–110 (2006).
   PubMed Web of Science ®Google Scholar
• Lee JH, O’Keefe JH, Lavie CJ, Harris WS. Omega-3 fatty acids: cardiovascular benefits, sources and sustainability. Nat. Rev. Cardiol.6, 753–758 (2009).
   PubMed Web of Science ®Google Scholar
• Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation105, 2107–2111 (2002).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360, 23–33 (2002).
   PubMed Web of Science ®Google Scholar
• Sesso HD, Buring JE, Christen WG et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA300, 2123–2133 (2008).
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil.14(Suppl. 2), S1–S113 (2007).
   PubMed Web of Science ®Google Scholar
• Tardif JC, McMurray JJ, Klug E et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet371, 1761–1768 (2008).
   PubMed Web of Science ®Google Scholar
• Miettinen TA, Gylling H. Regulation of cholesterol metabolism by dietary plant sterols. Curr. Opin. Lipidol.10, 9–14 (1999).
   PubMed Web of Science ®Google Scholar
• Devaraj S, Jialal I. The role of dietary supplementation with plant sterols and stanols in the prevention of cardiovascular disease. Nutr. Rev.64, 348–354 (2006).
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation106, 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med.333, 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Ford I, Murray H, Packard CJ et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N. Engl. J. Med.357, 1477–1486 (2007).
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arakawa K, Itakura H et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet368, 1155–1163 (2006).
   PubMed Web of Science ®Google Scholar
• Ridker PM. Moving toward new statin guidelines in a post-JUPITER world: principles to consider. Curr. Atheroscler. Rep.11, 249–256 (2009).
   PubMedGoogle Scholar
• Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet364, 685–696 (2004).
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344, 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352, 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA294, 2437–2445 (2005).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110, 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• White HD, Simes RJ, Anderson NE et al. Pravastatin therapy and the risk of stroke. N. Engl. J. Med.343, 317–326 (2000).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Bogousslavsky J, Callahan A 3rd et al. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med.355, 549–559 (2006).
   PubMed Web of Science ®Google Scholar
• Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: what have we learned about the benefits of statins from the acute coronary syndromes trials? Am. J. Cardiol.98, 18P–25P (2006).
   Google Scholar
• Cannon CP, Giugliano RP, Blazing MA et al. Rationale and design of IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am. Heart J.156, 826–832 (2008).
   PubMed Web of Science ®Google Scholar
• Kjekshus J, Apetrei E, Barrios V et al. Rosuvastatin in older patients with systolic heart failure. N. Engl. J. Med.357, 2248–2261 (2007).
   PubMed Web of Science ®Google Scholar
• Tavazzi L, Maggioni AP, Marchioli R et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet372, 1231–1239 (2008).
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V, Marz W et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med.353, 238–248 (2005).
   PubMed Web of Science ®Google Scholar
• Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev.58, 342–374 (2006).
   PubMed Web of Science ®Google Scholar
• Smith JD. Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler. Thromb. Vasc. Biol.30, 151–155 (2010).
   Google Scholar
• Rader DJ. Illuminating HDL – is it still a viable therapeutic target? N. Engl. J. Med.357, 2180–2183 (2007).
   PubMed Web of Science ®Google Scholar
• Glassberg H, Rader DJ. Management of lipids in the prevention of cardiovascular events. Annu. Rev. Med.59, 79–94 (2008).
   PubMed Web of Science ®Google Scholar
• Digby JE, Lee JM, Choudhury RP. Nicotinic acid and the prevention of coronary artery disease. Curr. Opin. Lipidol.20, 321–326 (2009).
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med.341, 410–418 (1999).
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet366, 1849–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Ginsberg HN, Elam MB, Lovato LC et al. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med.362, 1563–1574 (2010).
   PubMed Web of Science ®Google Scholar
• Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet375, 1875–1884 (2010).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation110, 3512–3517 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med.361, 2113–2122 (2009).
   PubMed Web of Science ®Google Scholar
• Parhofer KG. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc. Health Risk Manag.5, 901–908 (2009).
   PubMedGoogle Scholar
• Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med.357, 2109–2122 (2007).
   PubMed Web of Science ®Google Scholar
• Vergeer M, Bots ML, van Leuven SI et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation118, 2515–2522 (2008).
   PubMed Web of Science ®Google Scholar
• Krishna R, Anderson MS, Bergman AJ et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled Phase I studies. Lancet370, 1907–1914 (2007).
   PubMed Web of Science ®Google Scholar
• Briel M, Ferreira-Gonzalez I, You JJ et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. Br. Med. J.338, b92 (2009).
   PubMed Web of Science ®Google Scholar
• Chirovsky DR, Fedirko V, Cui Y, Sazonov V, Barter P. Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. Eur. J. Cardiovasc. Prev. Rehabil.16, 404–423 (2009).
   PubMedGoogle Scholar
• McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am. J. Cardiol.97, 89C–94C (2006).
   PubMed Web of Science ®Google Scholar
• Forsblom C, Hiukka A, Leinonen ES et al. Effects of long-term fenofibrate treatment on markers of renal function in Type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care33, 215–220 (2010).
   PubMed Web of Science ®Google Scholar
• Davidson M. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am. J. Cardiol.102, 19L–27L (2008).
   PubMedGoogle Scholar
• Sattar N, Preiss D, Murray HM et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet375, 735–742 (2010).
   PubMed Web of Science ®Google Scholar
• Teramoto T, Sasaki J, Ueshima H et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J. Atheroscler. Thromb.14, 45–50 (2007).
   PubMed Web of Science ®Google Scholar
• Kim JQ, Song J, Park YB et al. National cholesterol treatment guidelines in Korean population – setting-up the cutpoints for high blood cholesterol. J. Korean Med. Sci.12, 17–22 (1997).
   Google Scholar
• Barter P, Gotto AM, LaRosa JC et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med.357, 1301–1310 (2007).
   PubMed Web of Science ®Google Scholar
• Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J.24, 987–1003 (2003).
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Backer G et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur. J. Cardiovasc. Prev. Rehabil.16, 121–137 (2009).
   PubMed Web of Science ®Google Scholar
• Waters DD, Brotons C, Chiang CW et al. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation120, 28–34 (2009).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation107, 499–511 (2003).
   PubMed Web of Science ®Google Scholar
• Naghavi M, Libby P, Falk E et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation108, 1772–1778 (2003).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds risk score for men. Circulation118, 2243–2251 (2008).
   PubMed Web of Science ®Google Scholar
• Folsom AR, Chambless LE, Ballantyne CM et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch. Intern. Med.166, 1368–1373 (2006).
   PubMed Web of Science ®Google Scholar
• Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation109, 1349–1353 (2004).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA297, 611–619 (2007).
   PubMed Web of Science ®Google Scholar
• Wang TJ, Gona P, Larson MG et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med.355, 2631–2639 (2006).
   PubMed Web of Science ®Google Scholar
• Fuster V, Vahl TP. The role of noninvasive imaging in promoting cardiovascular health. J. Nucl. Cardiol. DOI: 10.1007/s12350-010-9264-9 (2010) (Epub ahead of print)
   Google Scholar
• Nambi V, Chambless L, Folsom AR et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J. Am. Coll. Cardiol.55, 1600–1607 (2010).
   PubMed Web of Science ®Google Scholar
• Caslake MJ, Packard CJ. Phenotypes, genotypes and response to statin therapy. Curr. Opin. Lipidol.15, 387–392 (2004).
   PubMed Web of Science ®Google Scholar
• Deedwania P, Barter P, Carmena R et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet368, 919–928 (2006).
   PubMed Web of Science ®Google Scholar
• Drexel H. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients? Fundam. Clin. Pharmacol.23, 687–692 (2009).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Betteridge J, Van Gaal L. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr. Med. Res. Opin.21, 665–682 (2005).
   PubMed Web of Science ®Google Scholar
• Hamilton P. Role of ezetimibe in the management of patients with atherosclerosis. Coron. Artery Dis.20, 169–174 (2009).
   Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr. Med. Res. Opin.23, 2009–2026 (2007).
   PubMed Web of Science ®Google Scholar
• Rossebo AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med.359, 1343–1356 (2008).
   PubMed Web of Science ®Google Scholar
• Peto R, Emberson J, Landray M et al. Analyses of cancer data from three ezetimibe trials. N. Engl. J. Med.359, 1357–1366 (2008).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Hong Y, Labarthe D et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation121, 586–613 (2010).
   PubMed Web of Science ®Google Scholar
• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract.87, 4–14 (2010).
   PubMed Web of Science ®Google Scholar
• Tuomilehto J. Nonpharmacologic therapy and exercise in the prevention of Type 2 diabetes. Diabetes Care32(Suppl. 2), S189–S193 (2009).
   Google Scholar
• Nathan DM. Navigating the choices for diabetes prevention. N. Engl. J. Med.360, 1533–1535 (2010).
   Google Scholar
• Fruchart JC, Sacks FM, Hermans MP et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab. Vasc. Dis. Res.5, 319–335 (2008).
   PubMed Web of Science ®Google Scholar
• Duffy D, Rader DJ. Update on strategies to increase HDL quantity and function. Nat. Rev. Cardiol.6, 455–463 (2009).
   PubMed Web of Science ®Google Scholar
• Paynter NP, Chasman DI, Pare G et al. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA303, 631–637 (2010).
   PubMed Web of Science ®Google Scholar
• Krauss RM, Mangravite LM, Smith JD et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation117, 1537–1544 (2008).
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy – a genomewide study. N. Engl. J. Med.359, 789–799 (2008).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pais P, Afzal R et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a Phase II, double-blind, randomised trial. Lancet373, 1341–1351 (2009).
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet375, 998–1006 (2010).
   PubMed Web of Science ®Google Scholar
• Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999–2006. JAMA302, 2104–2110 (2009).
   PubMed Web of Science ®Google Scholar